Dr. Roberto Calle is an endocrinologist with over 20 years of experience in drug development in the metabolism space. He is currently an Executive Medical Director in Clinical Sciences – General Medicine with Regeneron Pharmaceuticals. He is responsible for the late development metabolism portfolio for Regeneron, including NASH. Dr. Calle is also the Industry Co-chair for the Metabolic Disorders Steering Committee of the Foundation of the National Institutes of Health Biomarkers Consortium.